Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which CLL drug gives best bang for the buck? new study analyzes costs and patient Well-Being

NCT ID NCT02414022

Knowledge-focused Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. The goal is to help public health systems decide which treatment offers the best value.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ibrutinib, rituximab, bendamustine
What this could lead to
If successful, this could help healthcare systems decide which treatment offers the best value for money in older CLL patients.
What could go wrong
This is an economic analysis of a small subset of patients, not a new treatment trial. Results may not apply to all patients or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

Apr 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must be eligible for the core CLC.2/A041202 protocol. * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. * Patient must be able (i.e. sufficiently fluent), and willing to complete the health utilities questionnaire in English or French. The baseline assessment must be completed within required timelines, prior to registration/randomization Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the core protocol. However, ability but unwillingness to complete the questionnaires will make the patient ineligible for the core protocol. * Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

  • CHUM-CEntre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • CSSS Champlain-Charles LeMoyne

    Greenfield Park, Quebec, Canada

  • Health Sciences North

    Greater Sudbury, Ontario, Canada

  • Humber River Hospital

    Toronto, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L3N6, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Odette Cancer Centre Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Stronach Regional Health Centre at Southlake

    Newmarket, Ontario, L3Y 2P9, Canada

  • The Jewish General Hospital

    Montreal, Quebec, Canada

  • The Moncton Hospital

    Moncton, New Brunswick, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • University Health Network Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.